H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Cytokinetics (NASDAQ:CYTK) on Monday, setting a price target of $43, which is approximately 160.29% above the present share price of $16.52.
Pantginis expects Cytokinetics to post earnings per share (EPS) of -$0.05 for the fourth quarter of 2020.
The current consensus among 9 TipRanks analysts is for a Strong Buy rating of shares in Cytokinetics, with an average price target of $32.33.
The analysts price targets range from a high of $48 to a low of $16.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $41.69 million and a net profit of $5.18 million. The company's market cap is $1.17 billion.
According to TipRanks.com, H.C. Wainwright analyst Joseph Pantginis is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 26.3% and a 55.47% success rate.
Cytokinetics, Inc. operates as a biopharmaceutical company, which focuses on the discovery and development of muscle activators as potential treatment for debilitating diseases. It conducts a Phase 2 clinical trials program for tirasemtiv, including a Phase 2b clinical trial in patients with ALS, known as BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS). The company was founded on August 5, 1997 and is headquartered in South San Francisco, CA.